Zweig-DiMenna Associates’s Oric Pharmaceuticals ORIC Stock Holding History

Zweig-DiMenna Associates’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.62M	Buy	+268,790	New	+$3.35M	0.28%	73

Other funds holding ORIC

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Zweig-DiMenna Associates's ORIC Position: Q3 2026 in Review

Zweig-DiMenna Associates opened a new position in Oric Pharmaceuticals (ORIC) in Q3 2026: 268,790 shares worth $3.62M. The stake represents 0.28% of the portfolio and ranks #73 among its holdings.

48 funds tracked by Wall St. Rank hold ORIC as of Q3 2026.

Zweig-DiMenna Associates held 268,790 shares of Oric Pharmaceuticals worth $3.62M as of Q3 2026.
Oric Pharmaceuticals was a new Zweig-DiMenna Associates position in Q3 2026.
Oric Pharmaceuticals made up 0.28% of Zweig-DiMenna Associates's portfolio in Q3 2026, its #73 holding.
48 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2026.

Based on Zweig-DiMenna Associates's 13F filing for Q3 2026, filed 6 Nov 2026.